256 related articles for article (PubMed ID: 30554762)
1. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis.
Chen C; Cervero Liceras F; Flasche S; Sidharta S; Yoong J; Sundaram N; Jit M
Lancet Glob Health; 2019 Jan; 7(1):e58-e67. PubMed ID: 30554762
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia.
Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M
Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
Sohn HS; Suh DC; Jang E; Kwon JW
J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
[TBL] [Abstract][Full Text] [Related]
4. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M
Value Health; 2004; 7(1):36-51. PubMed ID: 14720129
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of pneumococcal conjugate vaccination in The Gambia.
Kim SY; Lee G; Goldie SJ
BMC Infect Dis; 2010 Sep; 10():260. PubMed ID: 20815900
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay.
Kieninger MP; Caballero EG; Sosa AA; Amarilla CT; Jáuregui B; Janusz CB; Clark AD; Castellanos RM
Vaccine; 2015 May; 33 Suppl 1():A143-53. PubMed ID: 25919155
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
9. Effect of the introduction of pneumococcal conjugate vaccination on invasive pneumococcal disease in The Gambia: a population-based surveillance study.
Mackenzie GA; Hill PC; Jeffries DJ; Hossain I; Uchendu U; Ameh D; Ndiaye M; Adeyemi O; Pathirana J; Olatunji Y; Abatan B; Muhammad BS; Fombah AE; Saha D; Plumb I; Akano A; Ebruke B; Ideh RC; Kuti B; Githua P; Olutunde E; Ofordile O; Green E; Usuf E; Badji H; Ikumapayi UNA; Manjang A; Salaudeen R; Nsekpong ED; Jarju S; Antonio M; Sambou S; Ceesay L; Lowe-Jallow Y; Jasseh M; Mulholland K; Knoll M; Levine OS; Howie SR; Adegbola RA; Greenwood BM; Corrah T
Lancet Infect Dis; 2016 Jun; 16(6):703-711. PubMed ID: 26897105
[TBL] [Abstract][Full Text] [Related]
10. Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.
Haasis MA; Ceria JA; Kulpeng W; Teerawattananon Y; Alejandria M
PLoS One; 2015; 10(7):e0131156. PubMed ID: 26131961
[TBL] [Abstract][Full Text] [Related]
11. Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya.
Ojal J; Griffiths U; Hammitt LL; Adetifa I; Akech D; Tabu C; Scott JAG; Flasche S
Lancet Glob Health; 2019 May; 7(5):e644-e654. PubMed ID: 31000132
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.
Sibak M; Moussa I; El-Tantawy N; Badr S; Chaudhri I; Allam E; Baxter L; Abo Freikha S; Hoestlandt C; Lara C; Hajjeh R; Munier A
Vaccine; 2015 May; 33 Suppl 1():A182-91. PubMed ID: 25919159
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan.
Shinjoh M; Togo K; Hayamizu T; Yonemoto N; Morii J; Perdrizet J; Kamei K
Expert Rev Vaccines; 2024; 23(1):485-497. PubMed ID: 38682661
[TBL] [Abstract][Full Text] [Related]
14. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico.
Wasserman M; Palacios MG; Grajales AG; Baez/Revueltas FB; Wilson M; McDade C; Farkouh R
Hum Vaccin Immunother; 2019; 15(3):560-569. PubMed ID: 30156978
[TBL] [Abstract][Full Text] [Related]
15. Pneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implications.
Pecenka C; Usuf E; Hossain I; Sambou S; Vodicka E; Atherly D; Mackenzie G
BMJ Glob Health; 2021 Dec; 6(12):. PubMed ID: 34916274
[TBL] [Abstract][Full Text] [Related]
16. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option.
Dorji K; Phuntsho S; Pempa ; Kumluang S; Khuntha S; Kulpeng W; Rajbhandari S; Teerawattananon Y
Vaccine; 2018 Mar; 36(13):1757-1765. PubMed ID: 29478752
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
Mo X; Gai Tobe R; Liu X; Mori R
Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.
Earnshaw SR; McDade CL; Zanotti G; Farkouh RA; Strutton D
BMC Infect Dis; 2012 Apr; 12():101. PubMed ID: 22530841
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
[TBL] [Abstract][Full Text] [Related]
20. Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies.
Mackenzie GA; Hill PC; Sahito SM; Jeffries DJ; Hossain I; Bottomley C; Uchendu U; Ameh D; Ndiaye M; Osuorah CD; Adeyemi O; Pathirana J; Olatunji Y; Abatan B; Ahameefula E; Muhammad BS; Fombah AE; Saha D; Mackenzie R; Plumb I; Akano A; Ebruke B; Ideh RC; Kuti B; Githua P; Olutunde E; Ofordile O; Green E; Usuf E; Badji H; Ikumapayi UNA; Manjang A; Salaudeen R; Nsekpong ED; Jarju S; Antonio M; Sambou S; Ceesay L; Lowe-Jallow Y; Sowe D; Jasseh M; Mulholland K; Knoll M; Levine OS; Howie SR; Adegbola RA; Greenwood BM; Corrah T
Lancet Infect Dis; 2017 Sep; 17(9):965-973. PubMed ID: 28601421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
